PABLO
RYAN MÚRUA
Profesor asociado
Hospital Universitari de Bellvitge
l'Hospitalet de Llobregat, EspañaPublicaciones en colaboración con investigadores/as de Hospital Universitari de Bellvitge (21)
2024
-
A Phase III Randomized Controlled Trial of Plitidepsin, a Marine-Derived Compound, in Hospitalized Adults With Moderate COVID-19
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, Vol. 79, Núm. 4, pp. 910-919
-
Novel risk loci for COVID-19 hospitalization among admixed American populations
eLife, Vol. 13
2023
-
A second update on mapping the human genetic architecture of COVID-19
Nature
-
Combined COVID-19 vaccination and hepatitis C virus screening intervention in marginalised populations in Spain
Communications Medicine, Vol. 3, Núm. 1
2022
-
Impact of early interferon-β treatment on the prognosis of patients with COVID-19 in the first wave: A post hoc analysis from a multicenter cohort
Biomedicine and Pharmacotherapy, Vol. 146
2021
-
Development and validation of a prediction model for 30-day mortality in hospitalised patients with COVID-19: The COVID-19 SEIMC score
Thorax, Vol. 76, Núm. 9, pp. 920-929
-
Identification and validation of clinical phenotypes with prognostic implications in patients admitted to hospital with COVID-19: a multicentre cohort study
The Lancet Infectious Diseases, Vol. 21, Núm. 6, pp. 783-792
-
Provirus reactivation is impaired in HIV-1 infected individuals on treatment with dasatinib and antiretroviral therapy
Biochemical Pharmacology, Vol. 192
-
Treatment with tocilizumab or corticosteroids for COVID-19 patients with hyperinflammatory state: a multicentre cohort study (SAM-COVID-19)
Clinical Microbiology and Infection, Vol. 27, Núm. 2, pp. 244-252
2020
-
Characteristics and predictors of death among 4035 consecutively hospitalized patients with COVID-19 in Spain
Clinical Microbiology and Infection, Vol. 26, Núm. 11, pp. 1525-1536
2019
-
Candidemia in solid organ transplant recipients in Spain: Epidemiological trends and determinants of outcome
Transplant Infectious Disease, Vol. 21, Núm. 6
2017
-
Evaluation of the possible influence of trailing and paradoxical effects on the clinical outcome of patients with candidemia
Clinical Microbiology and Infection, Vol. 23, Núm. 1, pp. 49.e1-49.e8
-
Impact of fluconazole susceptibility on the outcome of patients with candidaemia: data from a population-based surveillance
Clinical Microbiology and Infection, Vol. 23, Núm. 9, pp. 672.e1-672.e11
2016
-
Abacavir/lamivudine plus rilpivirine is an effective and safe strategy for HIV-1 suppressed patients: 48 week results of the SIMRIKI retrospective study
PLoS ONE, Vol. 11, Núm. 10
-
Effectiveness and safety of an abacavir/lamivudine + rilpivirine regimen for the treatment of HIV-1 infection in naive patients
Journal of Antimicrobial Chemotherapy, Vol. 71, Núm. 12, pp. 3510-3514
-
Empirical and targeted therapy of candidemia with fluconazole versus echinocandins: a propensity score–derived analysis of a population-based, multicentre prospective cohort
Clinical Microbiology and Infection, Vol. 22, Núm. 8, pp. 733.e1-733.e8
2015
-
A simple prediction score for estimating the risk of candidaemia caused by fluconazole non-susceptible strains
Clinical Microbiology and Infection, Vol. 21, Núm. 7, pp. 684.e1-684.e9
-
Candida tropicalis bloodstream infection: Incidence, risk factors and outcome in a population-based surveillance
Journal of Infection, Vol. 71, Núm. 3, pp. 385-394
-
Dual treatment with lopinavir-ritonavir plus lamivudine versus triple treatment with lopinavir-ritonavir plus lamivudine or emtricitabine and a second nucleos(t)ide reverse transcriptase inhibitor for maintenance of HIV-1 viral suppression (OLE): A randomised, open-label, non-inferiority trial
The Lancet Infectious Diseases, Vol. 15, Núm. 7, pp. 785-792
-
Epidemiology and outcome of candidaemia in patients with oncological and haematological malignancies: RESULTS from a population-based surveillance in Spain
Clinical Microbiology and Infection, Vol. 21, Núm. 5, pp. 491.e1-491.e10